Comparison of Gossamer Bio Inc. (GOSS) and Atara Biotherapeutics Inc. (NASDAQ:ATRA)

This is a contrast between Gossamer Bio Inc. (NASDAQ:GOSS) and Atara Biotherapeutics Inc. (NASDAQ:ATRA) based on their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gossamer Bio Inc. 21 -0.25 37.36M -2.32 0.00
Atara Biotherapeutics Inc. 13 0.00 28.74M -5.62 0.00

Table 1 highlights Gossamer Bio Inc. and Atara Biotherapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 represents Gossamer Bio Inc. (NASDAQ:GOSS) and Atara Biotherapeutics Inc. (NASDAQ:ATRA)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gossamer Bio Inc. 173,848,301.54% 0% 0%
Atara Biotherapeutics Inc. 221,076,923.08% -69.1% -61.9%

Liquidity

Gossamer Bio Inc.’s Current Ratio is 19.8 while its Quick Ratio is 19.8. On the competitive side is, Atara Biotherapeutics Inc. which has a 10 Current Ratio and a 10 Quick Ratio. Gossamer Bio Inc. is better positioned to pay off short and long-term obligations compared to Atara Biotherapeutics Inc.

Analyst Ratings

The following table delivered below contains the ratings and recommendations for Gossamer Bio Inc. and Atara Biotherapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Gossamer Bio Inc. 0 0 2 3.00
Atara Biotherapeutics Inc. 1 2 0 2.67

$31.5 is Gossamer Bio Inc.’s average target price while its potential upside is 21.34%. Competitively the average target price of Atara Biotherapeutics Inc. is $15.33, which is potential 8.34% upside. The data from earlier shows that analysts opinion suggest that Gossamer Bio Inc. seems more appealing than Atara Biotherapeutics Inc.

Insider & Institutional Ownership

Gossamer Bio Inc. and Atara Biotherapeutics Inc. has shares held by institutional investors as follows: 72.1% and 97%. 1.1% are Gossamer Bio Inc.’s share held by insiders. Comparatively, 2.3% are Atara Biotherapeutics Inc.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Gossamer Bio Inc. 6.95% -11.66% 19.08% 0% 0% 10.65%
Atara Biotherapeutics Inc. -5.25% -27.19% -56.31% -60.55% -60.2% -58.92%

For the past year Gossamer Bio Inc. had bullish trend while Atara Biotherapeutics Inc. had bearish trend.

Summary

On 9 of the 12 factors Gossamer Bio Inc. beats Atara Biotherapeutics Inc.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. Its clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. The company is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease. It has license agreements with Memorial Sloan Kettering Cancer Center and Amgen, Inc.; and license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute. The company also has a clinical trial collaboration agreement with Merck Sharp & Dohme B.V. to evaluate ATA129 in combination with Merck anti-programmed death receptor-1 therapy and Keytruda in patients with platinum resistant or recurrent epstein-barr virus-associated nasopharyngeal carcinoma. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.